secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2025-11-24T23:59:59+00:00
Accession:  0001493152-25-024818
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir Pharma reports Telomir-1 reduces PSA in prostate cancer cells in dose-related manner
--------------------------------------------------------------------------------

- Telomir-1 reduced PSA levels in dose-related manner in androgen-responsive human prostate cancer cells (LNCaP) in vitro.
- Also associated with reductions in cellular energy metabolism and viability in the same study.
- In prior PC3 xenograft mouse model, Telomir-1 reduced tumor volume as single agent; full reduction with paclitaxel combo without mortality.
- Paclitaxel alone achieved full tumor reduction but had high mortality; Telomir-1 combo showed no treatment-related deaths.
- Company advancing IND-enabling activities for planned IND submission across oncology and aging-related conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000149315225024818/0001493152-25-024818-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000149315225024818/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-024818

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer